Kyverna Therapeutics, Inc. Debt Securities, Available-for-Sale, Accrued Interest Writeoff
Kyverna Therapeutics, Inc. (KYTX) reported Debt Securities, Available-for-Sale, Accrued Interest Writeoff of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff · last filed 2026-08-11
- Kyverna Therapeutics, Inc. debt securities, available-for-sale, accrued interest writeoff for the quarter ending 2026-06-30 was $0.00.
- Kyverna Therapeutics, Inc. debt securities, available-for-sale, accrued interest writeoff for the quarter ending 2026-03-31 was $0.00.
- Kyverna Therapeutics, Inc. debt securities, available-for-sale, accrued interest writeoff for the quarter ending 2025-06-30 was $0.00.
- Kyverna Therapeutics, Inc. debt securities, available-for-sale, accrued interest writeoff for the quarter ending 2025-03-31 was $0.00.
- Kyverna Therapeutics, Inc. debt securities, available-for-sale, accrued interest writeoff for fiscal 2025 was $0.00.
- Kyverna Therapeutics, Inc. debt securities, available-for-sale, accrued interest writeoff for fiscal 2024 was $0.00.
- Kyverna Therapeutics, Inc. debt securities, available-for-sale, accrued interest writeoff for fiscal 2023 was $0.00.
| Period end | Debt Securities, Available-for-Sale, Accrued Interest Writeoff 3 month | Debt Securities, Available-for-Sale, Accrued Interest Writeoff 6 month | Debt Securities, Available-for-Sale, Accrued Interest Writeoff 9 month | Debt Securities, Available-for-Sale, Accrued Interest Writeoff 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |